NEOSH101
Development of NEOSH101 for androgenetic alopecia was discontinued by Neosil.
A topical proteasome inhibitor that reported a 4.8% hair-count gain in 2007 and was shelved by its acquirer two years later.
This programme is no longer being actively pursued.
- Developed by
- Neosil
- Current phase
- Discontinued
- Mechanism
- Other
- Partners
- Peplin, LEO Pharma
- Indications
- Androgenetic alopecia
- Also known as
- NEOSH-101, OSH101, tetrapeptide aldehyde proteasome inhibitor
- Last public activity
- May 2008
- Copy last reviewed
- September 2026
- Record confidence
- Medium
Development stopped.
A mechanism that doesn't fit the categories above.
A research record, not medical advice: being listed here says nothing about whether a treatment works or whether it is right for you. Talk to a dermatologist about your own case.
How it is meant to work
Registered as a tetrapeptide aldehyde proteasome inhibitor applied to the scalp. The registry gives no account of how proteasome inhibition was expected to act on the follicle.
Why it matters
A Phase 2a in Germany, 50 men, two 14-day courses of once-daily NEOSH101 or placebo a month apart, reported a 4.8% increase in total hair count and 3.7% in cumulative thickness in a January 2007 company release that did not say what the gains were measured against, and that never became a paper this register can find. Two larger studies registered in 2007, one of 180 men against 5% minoxidil and placebo that completed in April 2008 and a dose-ranging study of 140, posted no result. Peplin bought Neosil in October 2008 and wrote in its 2009 annual report that it was not conducting further development of the Neosil intellectual property; LEO Pharma agreed to buy Peplin that September, and the compound has not surfaced since. One of the earlier novel-mechanism topicals to disappear inside an acquisition.
Development history
- Phase 2
First Phase 2 trial on record: NCT00418730 — Efficacy Study of Topical NEOSH101 to Treat Male Pattern Hair Loss
ClinicalTrials.gov ↗
Registered trials
Pulled automatically from ClinicalTrials.gov. Matching is by name and development code, so occasional gaps are possible — tell us if you spot one.
Dose-Ranging Efficacy Study of Topical NEOSH101 to Treat Male Pattern Hair Loss
Neosil, Inc. · n=140 · May 2007
Efficacy Study of Topical NEOSH101 to Treat Male Pattern Hair Loss
Neosil, Inc. · n=180 · January 2007
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first.
Sources
- Efficacy Study of Topical NEOSH101 to Treat Male Pattern Hair Loss — ClinicalTrials.gov
- Dose-Ranging Efficacy Study of Topical NEOSH101 to Treat Male Pattern Hair Loss — ClinicalTrials.gov
- Peplin, Inc. Form 10-K for fiscal year 2009 — Regulator filing, September 2009
- Neosil announces positive Phase 2 data for NEOSH101, an investigational treatment for androgenetic alopecia (full text, Market Wire, archived) — Company release, January 2007
- Neosil Incorporated announces positive Phase 2 data for NEOSH101, an investigational treatment for androgenetic alopecia — Company release, January 2007
Related programmes
Other programmes in the register with the same approach.
Cite this page
Hair Pipeline, "NEOSH101 — development record", hairpipeline.com/pipeline/neosh101